Both miR526b and miR655 enhanced CSC phenotypes in both luminal A and HER2 positive breast cancer [8,9], and MYC expression in MCF7-miR655 cells is marginally upregulated [9]; however, MYC is a predicted target of miR655. The gene discussed is ERBB2; the disease is breast carcinoma.